397 related articles for article (PubMed ID: 36810060)
21. Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy.
Ferrante N; Ritrovato D; Bitonti R; Furneri G
BMC Health Serv Res; 2022 Apr; 22(1):573. PubMed ID: 35484540
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration.
Razavi S; Kodjikian L; Giocanti-Aurégan A; Dufour I; Souied E
BMC Ophthalmol; 2021 Feb; 21(1):90. PubMed ID: 33596867
[TBL] [Abstract][Full Text] [Related]
24. Comparative Efficacy of Brolucizumab in the Treatment of Neovascular Age-Related Macular Degeneration: A Systematic Literature Review and Network Meta-Analysis.
Finger RP; Dennis N; Freitas R; Quenéchdu A; Clemens A; Karcher H; Souied EH
Adv Ther; 2022 Aug; 39(8):3425-3448. PubMed ID: 35678996
[TBL] [Abstract][Full Text] [Related]
25. [Anti-VEGF therapy for neovascular age-related macular degeneration: causes of incomplete response].
Zaytseva OV; Neroeva NV; Okhotsimskaya TD; Bobykin EV
Vestn Oftalmol; 2021; 137(5):152-159. PubMed ID: 34726870
[TBL] [Abstract][Full Text] [Related]
26. Four-week outcomes of vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration.
Wiryasaputra S; Nguyen V; Arnold JJ; Ferrier R; Hinchcliffe P; Barthelmes D; Gillies MC
Clin Exp Ophthalmol; 2020 Sep; 48(7):946-955. PubMed ID: 32463528
[TBL] [Abstract][Full Text] [Related]
27. Comparison of agents using higher dose anti-VEGF therapy for treatment-resistant neovascular age-related macular degeneration.
Broadhead GK; Keenan TDL; Chew EY; Wiley HE; Cukras CA
Graefes Arch Clin Exp Ophthalmol; 2022 Jul; 260(7):2239-2247. PubMed ID: 35092447
[TBL] [Abstract][Full Text] [Related]
28. Twelve-month outcomes of intra-vitreal anti-VEGF agents for treatment-naïve neovascular age-related macular degeneration eyes: French data from the fight for retinal blindness!
Lestable L; Gabrielle PH; Bron AM; Nguyen P; Creuzot-Garcher C
J Fr Ophtalmol; 2020 Oct; 43(8):761-769. PubMed ID: 32622633
[TBL] [Abstract][Full Text] [Related]
29. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
[TBL] [Abstract][Full Text] [Related]
30. Real-Life Experience with Aflibercept and Ranibizumab in the Treatment of Newly Diagnosed Neovascular Age-Related Macular Degeneration over 24 Months.
Garweg JG; Gerhardt C; Kodjikian L; Pfister IB
J Ocul Pharmacol Ther; 2017 Sep; 33(7):567-572. PubMed ID: 28557667
[TBL] [Abstract][Full Text] [Related]
31. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.
Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH
Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633
[TBL] [Abstract][Full Text] [Related]
32. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records.
Kiss S; Campbell J; Almony A; Shih V; Serbin M; LaPrise A; Wykoff CC
Ophthalmology; 2020 Sep; 127(9):1179-1188. PubMed ID: 32345477
[TBL] [Abstract][Full Text] [Related]
33. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
[TBL] [Abstract][Full Text] [Related]
34. Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
Jampol LM; Glassman AR; Liu D; Aiello LP; Bressler NM; Duh EJ; Quaggin S; Wells JA; Wykoff CC;
Ophthalmology; 2018 Jul; 125(7):1054-1063. PubMed ID: 29525602
[TBL] [Abstract][Full Text] [Related]
35. [Effect of intravitreal injections of ranibizumab and aflibercept on the retinal nerve fiber layer in patients with concomitant neovascular age-related macular degeneration and glaucoma].
Rud'ko AS; Budzinskaya MV; Andreeva IV; Karpilova MA; Smirnova TV
Vestn Oftalmol; 2019; 135(5. Vyp. 2):177-183. PubMed ID: 31691657
[TBL] [Abstract][Full Text] [Related]
36. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
37. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ
Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437
[TBL] [Abstract][Full Text] [Related]
38. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
Wells JA; Glassman AR; Ayala AR; Jampol LM; Bressler NM; Bressler SB; Brucker AJ; Ferris FL; Hampton GR; Jhaveri C; Melia M; Beck RW;
Ophthalmology; 2016 Jun; 123(6):1351-9. PubMed ID: 26935357
[TBL] [Abstract][Full Text] [Related]
39. Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems.
Finger RP; Daien V; Eldem BM; Talks JS; Korobelnik JF; Mitchell P; Sakamoto T; Wong TY; Pantiri K; Carrasco J
BMC Ophthalmol; 2020 Jul; 20(1):294. PubMed ID: 32680477
[TBL] [Abstract][Full Text] [Related]
40. Creation of a neovascular age-related macular degeneration national database using a web-based platform: Fight Retinal Blindness Spain. Report 1: Visual outcomes.
Zarranz-Ventura J; Parrado-Carrillo A; Nguyen V; Sararols L; Garay-Aramburu G; Puzo M; Arruabarrena C; Figueras-Roca M; Gillies MC; Casaroli-Marano RP;
Clin Exp Ophthalmol; 2022 Apr; 50(3):312-324. PubMed ID: 35106882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]